In the BioHarmony Drug Report Database

"Preview" Icon

Drospirenone

Slynd, Drovelis, Lydisilka (drospirenone) is a small molecule pharmaceutical. Drospirenone was first approved as Slynd on 2019-05-23. It has been approved in Europe to treat contraception. The pharmaceutical is active against mineralocorticoid receptor. Yasmin’s patent is valid until 2031-06-28 (FDA).

 

Trade Name

 

Drovelis, Lydisilka
 

Common Name

 

drospirenone
 

ChEMBL ID

 

CHEMBL1509
 

Indication

 

contraception
 

Drug Class

 

Aldosterone antagonists (spironolactone type)

Image (chem structure or protein)

Drospirenone structure rendering